Fly News Breaks for January 10, 2020
Jan 10, 2020 | 11:38 EDT
Piper Sandler analyst Tyler Van Buren said news of the amended collaboration between Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was "a positive update all around" as he believes the new registrational trials in adjuvant melanoma and muscle-invasive bladder cancer essentially expand the commercial opportunity for what are two of the more promising datasets and Bristol's "reset" in first-line lung cancer "is a neutral announcement as no one provided credit for lung anyway" to Nektar. Van Buren, who also contends that "the refined development plan in RCC makes a ton of sense," keeps an Overweight rating on Nektar shares.
News For NKTR;BMY From the Last 2 Days
There are no results for your query NKTR;BMY